Staar Surgical Co: Form 10-Q for the period ended Apr 3, 2020
Filed with the SEC on May 6, 2020 and accepted by EDGAR at May 6, 2020, 16:12 ET.
Management's discussion and analysis
As filed, 23,692 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The matters addressed in this Item 2 that are not historical information constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can recognize forward-looking statements by the use of words like “anticipate,” “estimate,” “expect,” “intend,” “plan,” “believe,” “will,” “should,” “forecast” and similar expressions in connection with any discussion of future operating or financial performance. In particular, these include statements about any of the following: any projections of or guidance as to earnings, revenue, sales, profit margins, expense rate, cash, effective tax rate, capital expense or any other financial items; the expected impact of the COVID-19 pandemic and related public health measures (including but not limited to their impact on sales, operations or clinical trials globally), the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; statements regarding new, existing, or improved products, including but not limited to, expectations for success of new, existing, and improved products in the U.S. or international markets or government approval of a new or improved products (including the EVO family of lenses in the U.S. and the EDOF ICL for presbyopia internationally); commercialization of new or improved products; future economic conditions or size of market opportunities; expected costs of operations; statements of belief, including as to achieving 2020 business plans; expected regulatory activities and approvals, product launches, and any statements of assumptions underlying any of the foregoing.
Although we believe that the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risks and we can give no assurance that our expectations will prove to be correct. Actual results could differ from those described in this report because of numerous factors, many of which are beyond our control. These factors include, without limitation, risks and uncertainties related to the COVID-19 pandemic and related public health measures, and those described in in our Annual Report on Form 10-K in “Item 1A. Risk Factors” filed on February 26, 2020, as well as the updated risk factor disclosed herein. We undertake no obligation to update these forward-looking statements after the date of this report to reflect future events or circumstances or to reflect actual outcomes.
The following discussion should be read in conjunction with the audited consolidated financial statements of STAAR, including the related notes, provided in this report.
Overview
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and companion delivery systems used to deliver the lenses into the eye. We are the world’s leading manufacturer of intraocular lenses for patients seeking refractive vision correction, and we also make lenses for use in surgery to treat cataracts. All the lenses we make are foldable, which allows the surgeon to insert them into the eye through a small incision during minimally invasive surgery. Refractive surgery is performed to treat the type of visual disorders that have traditionally been corrected using eyeglasses or contact lenses. We refer to our lenses used in refractive surgery as “implantable Collamer® lenses” or “ICLs.” The field of refractive surgery includes both lens-based procedures, using products like our ICL family of products, and laser-based procedures like LASIK. Successful refractive surgery can correct common vision disorders such as myopia, hyperopia, and astigmatism. Cataract surgery is a common outpatient procedure where the eye’s natural lens that has become cloudy with age is removed and replaced with an artificial lens called an intraocular lens (IOL) to restore the patient’s vision. STAAR employs a commercialization strategy that strives for sustainable profitable growth. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. We position our IOL lenses used in surgery that treats cataracts based on quality and value.
Recent Developments
Net Sales increased 8% over the prior year quarter despite COVID-19 headwinds causing a pause in elective procedures across different markets and of various durations, commencing in February in China. ICL units increased 9% over the prior year quarter, including growth in Japan of 79%, growth in Korea of 14%, growth in Canada of 10%, growth in China of 7% and growth in Germany of 5%. We expect the decrease in sales in certain geographies, such as parts of Europe and North America, to continue through the second quarter of 2020 and possibly beyond as governments and other organizations impose or recommend, and businesses and individuals implement, restrictions on various activities or other actions to combat this pandemic’s spread. We also expect business to resume in various global geographies as pandemic concerns subside, such as the current experience in China and the nascent experience in Germany. At this point, the extent to which the coronavirus may impact our business remains uncertain.
To date, we have not experienced any significant COVID-19 related supply chain challenges. Current levels of customer demand in the quarter, coupled with our temporary manufacturing closure, will lead to modestly longer lead times for certain “made to order” lenses. We resumed production on April 27, 2020, at our Monrovia and Aliso Viejo, California manufacturing facilities. As previously disclosed, we continued to pay all of our employees’ salaries, commissions, wages and benefits throughout the pandemic. We implemented enhanced safety measures intended to keep our employees safe, and our business continuity plans anticipate those measures remaining for some time, as well as potentially new measures identified as “best practices” in the future. In addition, we continue to monitor our customer’s return to work efforts, patient interest in refractive procedures in our larger markets, and our operational ability to meet expected customer demand. We gained valuable experience honing our digital communication strategies for providing customer educational and marketing support activities previously provided in person. We will continue to leverage and further improve these strategies for use into the foreseeable future as circumstances dictate. We remain confident that the future of refractive surgery is lens-based, and that our ICLs offer an exceptional solution for patients seeking visual freedom from contact lenses and eyeglasses.
With respect to our U.S. EVO clinical trial, our contract research organization is providing clinical-study support to the EVO principal investigators, including the restart of patient enrollment following a pause associated with recommendations from states and medical societies with respect to elective procedures and clinical trials. Several of our principal investigator sites have already reopened, and resumed patient recruiting, screening and implantation. At this time, we expect all of our principal investigator sites to reopen by May 15, 2020. Our EVO EDOF lens for presbyopia remains under review by DEKRA, our Notified Body. The pandemic may cause a delay in DEKRA’s response to our submission. Still, we remain optimistic our EDOF lens will be approved and introduced, in a staged rollout, to CE Mark countries either in the second or third quarter of this year. In early April 2020, we learned that Brazil’s Health Regulatory Agency, Anvisa, renewed the approval of the EVO Visian ICL for promotion and sale in Brazil after a protracted review. We expect to resume sales in Brazil in the second quarter of 2020, subject to the potential impact of COVID-19 on surgeons or patients.
Critical Accounting Policies
This Management’s Discussion and Analysis of Financial Condition and Results of Operations discusses and analyzes data in our unaudited Condensed Consolidated Financial Statements provided in this report, which we have prepared in accordance with U.S. generally accepted accounting principles. Preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual conditions may differ from our assumptions and actual results may differ from our estimates.
An accounting policy is deemed critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements. Management believes that there have been no significant changes during the three months ended April 3, 2020 to the items that we disclosed as our critical accounting policies and estimates in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended January 3, 2020.
Results of Operations
The following table shows the percentage of our total sales represented by certain items reflected in our Condensed Consolidated Statements of Operations for the periods indicated.
| Percentage of Net Sales for Three Months April 3, 2020 | March 29, 2019 | |
|---|---|---|
| Net sales | 100.0% | 100.0% |
| Cost of sales | 29.6% | 25.8% |
| Gross profit | 70.4% | 74.2% |
| General and administrative | 22.6% | 21.0% |
| Marketing and selling | 31.4% | 31.1% |
| Research and development | 19.6% | 17.3% |
| Total selling, general and administrative | 73.6% | 69.4% |
| Operating income (loss) | (3.2)% | 4.8% |
| Total other income (expense), net | (0.5)% | 0.9% |
| Income (loss) before income taxes | (3.7)% | 5.7% |
| Provision (benefit) for income taxes | (3.3)% | 1.5% |
| Net income (loss) | (0.4)% | 4.2% |
Net Sales
| Three Months Ended April 3, 2020 | March 29, 2019 | Percentage Change 2020 vs. 2019 | |
|---|---|---|---|
| ICLs | $29,340 | $27,786 | 5.6% |
| Other product sales | |||
| IOLs | 3,994 | 4,017 | (0.6)% |
| Other surgical products | 1,853 | 780 | 137.6% |
| Total other product sales | 5,847 | 4,797 | 21.9% |
| Net sales | $35,187 | $32,583 | 8.0% |
Net sales for the three months ended April 3, 2020 were $35.2 million, an increase of 8% from $32.6 million reported during the same period of 2019. The increase in net sales was due to an increase in ICL sales of $1.6 million and an increase in other product sales of $1.0 million.
Total ICL sales for the three months ended April 3, 2020 were $29.3 million, a 6% increase from $27.8 million reported for the same period of 2019, with unit growth up 9%. The sales increase was driven by the APAC region, which grew 10% with unit growth of 13%, primarily due to unit growth Japan up 79%, Korea up 14% and other APAC distributors up 37%. China sales, although essentially flat during the quarter, resumed in March 2020 after a country wide shut down in February 2020 as a result of the COVID-19 pandemic. The Europe, Middle East, Africa and Latin America region sales decreased 4% with unit decrease of 3%. The North America region sales decreased 5%, with unit decrease of 4%, primarily due to a unit decrease of 6% in the U.S., partially offset by a 10% unit increase in Canada. ICL sales represented 83.4% and 85.3% of our total sales for the three months ended April 3, 2020 and March 29, 2019, respectively.
Other product sales, including IOLs were $5.8 million for the three months ended April 3, 2020, an increase of 22% from $4.8 million reported for the same period of 2019. The increase is due to the increase in preloaded injector part sales to a third-party manufacturer for product they sell to their customers for the three months ended April 3, 2020. Other product sales represented 16.6% and 14.7% of our total sales for the three months ended April 3, 2020 and March 29, 2019, respectively.
Gross Profit
| Three Months Ended April 3, 2020 | March 29, 2019 | Percentage Change 2020 vs. 2019 | |
|---|---|---|---|
| Gross profit | $24,760 | $24,180 | 2.4% |
| Gross margin | 70.4% | 74.2% |
Gross profit for the three months ended April 3, 2020 was $24.8 million, a 2.4% increase compared to the $24.2 million reported for the same period of 2019. Gross profit margin decreased to 70.4% of revenue for the three months ended April 3, 2020 compared to 74.2% of revenue for the three months ended March 29, 2019, due primarily to period costs associated with manufacturing expansion projects and increased mix of injector part sales which carry a lower margin. Also impacting gross profit were $150,000 in period costs recorded as a result of COVID-19 and the resulting manufacturing pause which began on March 17, 2020. It is anticipated, gross profit in the second quarter of 2020 will be negatively impacted by approximately $1.4 million in additional period costs. Future gross profit will also likely be impacted by additional investments in safety-related modifications to our facilities, purchases of personal protective equipment (PPE) and other costs to protect against COVID-19, although the financial impact of this cannot yet be quantified. We resumed manufacturing on April 27, 2020.
General and Administrative Expense
| Three Months Ended April 3, 2020 | March 29, 2019 | Percentage Change 2020 vs. 2019 | |
|---|---|---|---|
| General and administrative expense | $7,969 | $6,837 | 16.6% |
| Percentage of sales | 22.6% | 21.0% |
General and administrative expenses for the three months ended April 3, 2020 were $8.0 million, a 16.6% increase compared to the $6.8 million reported for the same period of 2019. The increase in general and administrative expenses was due to an increase in headcount and salary-related expenses, increased tax consulting costs and increased facilities costs.
Marketing and Selling Expense
| Three Months Ended April 3, 2020 | March 29, 2019 | Percentage Change 2020 vs. 2019 | |
|---|---|---|---|
| Marketing and selling expense | $11,028 | $10,143 | 8.7% |
| Percentage of sales | 31.3% | 31.1% |
Marketing and selling expenses for the three months ended April 3, 2020 were $11.0 million, an 8.7% increase compared to the $10.1 million reported for the same period of 2019. The increase in marketing and selling expenses is due to increased advertising and promotional activities and increased headcount and salary-related expenses, partially offset by a decrease in travel expenses.
Research and Development Expense
| Three Months Ended April 3, 2020 | March 29, 2019 | Percentage Change 2020 vs. 2019 | |
|---|---|---|---|
| Research and development expense | $6,898 | $5,635 | 22.4% |
| Percentage of sales | 19.6% | 17.3% |
Research and development expenses for the three months ended April 3, 2020 were $6.9 million, a 22.4% increase compared to the $5.6 million reported for the same period of 2019. The increase for the was primarily due to an increase in in expenses related to clinical expenses associated with our EVO clinical trial in the U.S., increased quality validation expenses and increased headcount and salary-related expenses.
Other Income (Expense), Net
| Three Months Ended April 3, 2020 | March 29, 2019 | Percentage Change 2020 vs. 2019 | |
|---|---|---|---|
| Other income (expense), net | $(157) | $291 | —* |
| Percentage of sales | (0.5)% | 0.9% |
* Denotes change is greater than +100%.
Other expense, net for the three months ended April 3, 2020 was $0.2 million compared to other income of $0.3 million reported for the same period of 2019. The change in other income (expense), net was mainly due to an increase in foreign exchange losses (primarily the euro).
Income Taxes
| Three Months Ended April 3, 2020 | March 29, 2019 | Percentage Change 2020 vs. 2019 | |
|---|---|---|---|
| Income tax provision (benefit) | $(1,158) | $489 | —* |
* Denotes change is greater than +100%.
We recorded an income tax benefit of $1.2 million for the three months ended April 3, 2020 due to the income tax benefit from the release of our U.S. valuation allowances, offset by income tax expense from profits generated by our foreign operations. We recorded income taxes of $0.5 million for the three months ended March 29, 2019 primarily due to pre-tax income generated in certain foreign jurisdictions and withholding taxes on foreign operations. In the fourth quarter of fiscal year 2019, we reversed all previously recorded withholding taxes recorded for 2019, at which time we formed STAAR Surgical UK Limited as a holding company for our foreign operations. Based on the current tax treaties between the U.S., United Kingdom and Switzerland, we will no longer accrue for Switzerland withholding taxes on foreign earnings after fiscal 2018 (see also Note 10 in our fiscal 2019 Form 10-K for more information). We have no unrecognized tax benefits pertaining to any uncertain tax positions as of any period presented.
ASC 740 requires that a valuation allowance be established when it is more likely than not that all or a portion of a deferred tax asset may not be realizable. As further described in Notes 1 and 10 of our fiscal 2019 Form 10-K, under the “incremental cash tax savings approach,” we recorded a valuation release of $3,003,000 and $373,000 against federal and certain states deferred tax assets, respectively. During the three months ended April 3, 2020, we revised our global forecasts as a result of COVID-19, and released an additional $1.4 million of valuation allowance. As of April 3, 2020, we released approximately $4.9 million of valuation allowance on our deferred tax assets in the U.S. jurisdiction utilizing the incremental cash tax savings approach. The ultimate realization of deferred tax assets is dependent upon future generation of income during the periods in which temporary differences representing net future deductible amounts become deductible. We considered the projected future income, tax planning strategies and all other available evidence both positive and negative, as well as results of recent operations in making this assessment. In applying the incremental cash tax savings approach, we will continue to maintain a valuation allowance on the balance of the Company’s net U.S. deferred tax assets of $36.3 million.
Liquidity and Capital Resources
We believe that current cash, cash equivalents and future cash flow from operating activities will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the financial statements included in this quarterly report. We have experienced delays in payments on accounts receivable and expect this to continue to be the case during the second quarter as our customers are permitted to resume elective refractive surgery. This will have a temporary impact on our working capital. However, at this time we are unaware of any impairment of assets resulting from the COVID19 pandemic. The Company did not apply for or require financing available under the Coronavirus Aid, Relief, and Economic Security “CARES” Act and does not expect to do so given the strength of our balance sheet. Our financial condition at April 3, 2020 and January 3, 2020 included the following (in millions):
| April 3, 2020 | January 3, 2020 | 2020 vs. 2019 | |
|---|---|---|---|
| Cash and cash equivalents | $110.9 | $120.0 | $(9.1) |
| Current assets | $172.1 | $174.7 | $(2.6) |
| Current liabilities | 29.9 | 34.5 | (4.6) |
| Working capital | $142.2 | $140.2 | $2.0 |
We invest the net proceeds in short-term interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. Additionally, at April 3, 2020, we have a line of credit with a Japanese lender, in the amount of $1.3 million, with $3.3 million of availability and a line of credit with a Swiss lender, in the amount of $1.0 million, which is fully available for borrowing.
Net cash used in operating activities was $8.2 million for the three months ended April 3, 2020 compared to net cash provided by operating activities of $0.7 million for the three months ended March 29, 2019. Net cash used in operating activities for the three months ended April 3, 2020, consisted of $11.0 million in working-capital changes and a $0.1 million net loss, offset by $2.9 in non-cash items. The change in net cash used in operating activities during the three months ended April 3, 2020 was due to a decrease in net working capital of $5.8 million, a decrease of $1.6 million in non-cash items and the net loss of $0.1 million during the three months ended April 3, 2020 compared to net income of $1.4 million during the three months ended March 29, 2019.
Net cash used in investing activities was $2.2 million for the three months ended April 3, 2020 and March 29, 2019, respectively, and relate primarily to the acquisition of property, plant, and equipment.
Net cash provided by financing activities was $1.3 million for the three months ended April 3, 2020 compared to net cash used in financing activities of $0.2 million for the three months ended March 29, 2019. Net cash provided by financing activities for the three months ended April 3, 2020 consisted of $2.0 million of proceeds from the exercise of stock options, offset by $0.5 million repayment on the Japan line of credit and $0.2 million repayment of finance lease obligations.
Credit Facilities and Commitments
Lines of Credit and Leases
See Notes 7 and 8 of the accompanying Condensed Consolidated Financial Statements.
Covenant Compliance
The Company is in compliance with the covenants of its credit facilities as of April 3, 2020.
Employment Agreements
The Company’s Chief Executive Officer entered into an employment agreement with the Company, effective March 1, 2015. She and certain officers have as provisions of their agreements certain rights, including continuance of cash compensation and benefits, upon a “change in control,” which may include an acquisition of substantially all of its assets, or termination “without cause or for good reason” as defined in the employment agreements.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements, as that term is defined in the rules of the SEC, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.
Market risk
As filed, 239 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
During the three months ended April 3, 2020, there have been no material changes in the Company’s qualitative and quantitative market risk since the disclosure in the Company’s Annual Report on Form 10-K for the year ended January 3, 2020.
Controls and procedures
As filed, 3,361 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Disclosure Controls and Procedures
As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of the design and operation of the disclosure controls and procedures of the Company. Based on that evaluation, our CEO and CFO concluded, as of the end of the period covered by this quarterly report on Form 10-Q, that our disclosure controls and procedures were effective. For purposes of this statement, the term “disclosure controls and procedures” means controls and other procedures of the Company that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Our management, including the CEO and the CFO, do not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud or material errors. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations on all internal control systems, our internal control system can provide only reasonable assurance of achieving its objectives and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of internal control is also based in part upon certain assumptions about the likelihood of future events, and can provide only reasonable, not absolute, assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in circumstances, or the degree of compliance with the policies and procedures may deteriorate.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended April 3, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 5,522 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our short and long-term success is subject to many factors that are beyond our control. Investors and prospective investors should consider carefully information contained in this report and the risks and uncertainties described in “Part I—Item 1A—Risk Factors” of the Company’s Form 10-K for the fiscal year ended January 3, 2020. Such risks and uncertainties could materially adversely affect our business, financial condition or operating results.
In light of the ongoing COVID-19 pandemic, the Company has updated the risk factor set forth below. This risk factor supplements and should be read in conjunction with the risk factors described in the 2019 Form 10-K.
As discussed below, the impact of the COVID-19 pandemic and the measures implemented by governmental authorities and other third parties in response to the pandemic remains uncertain. To the extent the pandemic adversely affects our business, financial condition and results of operations, it may also have the effect of amplifying many of the risk factors included in Part 1, Item 1A, Risk Factors of the 2019 Form 10-K.
Public health crises, political crises, and other catastrophic events or other events outside of our control may impact our business.
In 2019, we generated approximately 95% of our total sales outside the U.S. A natural disaster (such as tsunami, power shortage, or flood), public health crisis (such as a pandemic or epidemic), political crisis (such as terrorism, war, political instability or other conflict), or other events outside of our control that may occur anywhere around the world, may adversely impact our business and operating results. Moreover, these types of events could negatively impact surgeon or patient spending in the impacted region(s) or depending upon the severity, globally, which could adversely impact our operating results. For example, in December 2019, COVID-19 was reported in Wuhan, China, resulting in temporary hospital and clinic closures and a decrease in consumer traffic in China, our largest single market. Thereafter, COVID-19 spread globally becoming a pandemic, resulting in governmental authorities and other third parties implementing or recommending a number of measures to contain the spread of COVID-19, including travel restrictions, shelter-in-place orders and business limitations and shutdowns. The impact of COVID-19 and these measures implemented or recommended by governmental authorities and other third parties have had a significant impact on many businesses, including ours. We suspended most of our production on March 17, 2020 with the exception of continuation of critical late-staged processes. Moreover, our revenues have been adversely impacted, as customers in China were not able to carry out procedures during the month of February and we experienced a substantial slowdown in sales beginning March 20, 2020 in global geographies characterized as “hot spots” for the COVID-19 virus, including parts of Europe and North America. In certain of these markets, sales have paused as elective surgeries are discouraged to support COVID-19 related needs. We expect this decrease in sales in certain geographies, such as parts of Europe and North America, to continue through the second quarter of 2020 and possibly beyond as different geographies resume business activities on differing timelines. We cannot predict when different governments will permit businesses in their jurisdictions to return to business or when consumers will resume scheduling procedures. We also cannot predict COVID-19’s impact on the overall economy of various markets, including the existence or extent of a possible recession. Thus, at this point, the extent to which the coronavirus may impact delayed medical procedures and delayed lens orders, and the related impact on our full year 2020 results is uncertain; however, it could have a material adverse impact on our results of operations, cash flows and financial condition. We monitor such events and take actions that we deem reasonable given the circumstances. In the future other types of crises, may create an environment of business uncertainty around the world, which may hinder sales and/or supplies of our products nationally and internationally.
The extent to which the pandemic impacts our business, operations, and financial results, including the duration and magnitude of such effects, will depend on numerous evolving factors that are uncertain and cannot be predicted, including the following: the duration and scope of the pandemic; the impact it has on global and regional economies and economic activity, including the duration and magnitude of its impact on consumer spending; how quickly and to what extent more customary economic and operating conditions can resume; its impact on our customers’ facilities; levels of consumer confidence; whether our COVID-19 preventative measures such as remote working arrangements, changes to manufacturing work areas, such as adherence to social distancing guidelines, and other workforce changes will impact operational efficiency or inventory levels; the impact on regulatory agencies, including the review and approval process; the impact on clinical studies; the ability of our customers to successfully navigate the impacts of the pandemic such as resuming activities and growing patient interest in our lenses; actions governments, businesses and individuals take in response to the pandemic; and potential employee illness and its impact on our operations.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-04-03. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-01-04 to 2020-04-03 | $5.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-01-04 to 2020-04-03 | $10.4m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2020-01-04 to 2020-04-03 | $24.8m | us-gaap:GrossProfit |
| Research and development | 3 months2020-01-04 to 2020-04-03 | $6.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2020-01-04 to 2020-04-03 | $25.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-01-04 to 2020-04-03 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2020-01-04 to 2020-04-03 | −$1.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-01-04 to 2020-04-03 | −$134.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-01-04 to 2020-04-03 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-01-04 to 2020-04-03 | $0.00 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-01-04 to 2020-04-03 | 44,953,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2020-01-04 to 2020-04-03 | −$8.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2020-01-04 to 2020-04-03 | $2.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-04-03 | $110.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-04-03 | $172.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-04-03 | $206.8m | us-gaap:Assets |
| Current liabilities | At period end2020-04-03 | $29.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-04-03 | $41.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-04-03 | $165.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-20-021932. Last ingested by Listed: Nov 4, 2026, 17:00 ET. Listed shows no prices and gives no investment advice.